Zhejiang Dayang Biotech Group Co (003017) — Capital Reinvestment Ratio
Zhejiang Dayang Biotech Group Co (003017) has a Capital Reinvestment Ratio of 27.69x as of September 2025, meaning it reinvests 28% of its operating cash flow (CN¥638.25K) in capital expenditures (CN¥17.67 Million). See 003017 equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Dayang Biotech Group Co Capital Reinvestment Ratio (2013–2025)
This chart tracks Zhejiang Dayang Biotech Group Co's Capital Reinvestment Ratio across 12 annual periods. Check cash flow reinvestment rate of Zhejiang Dayang Biotech Group Co to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Zhejiang Dayang Biotech Group Co (2013–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Dayang Biotech Group Co from 2013 to 2025. For live market cap and broader valuation context, see Zhejiang Dayang Biotech Group Co stock valuation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.48x | CN¥160.11 Million | CN¥76.38 Million | ▼ -50.2% |
| 2024 | 0.96x | CN¥66.19 Million | CN¥63.45 Million | ▲ +68.7% |
| 2023 | 0.57x | CN¥182.42 Million | CN¥103.63 Million | ▼ -50.1% |
| 2022 | 1.14x | CN¥91.89 Million | CN¥104.65 Million | ▲ +2.6% |
| 2020 | 1.11x | CN¥112.49 Million | CN¥124.82 Million | ▲ +102.9% |
| 2019 | 0.55x | CN¥113.09 Million | CN¥61.84 Million | ▼ -51.9% |
| 2018 | 1.14x | CN¥38.77 Million | CN¥44.05 Million | ▲ +106.7% |
| 2017 | 0.55x | CN¥48.64 Million | CN¥26.73 Million | ▼ -8.7% |
| 2016 | 0.60x | CN¥84.63 Million | CN¥50.95 Million | ▼ -32.4% |
| 2015 | 0.89x | CN¥48.95 Million | CN¥43.57 Million | ▲ +31.6% |
| 2014 | 0.68x | CN¥57.73 Million | CN¥39.04 Million | ▲ +50.8% |
| 2013 | 0.45x | CN¥91.64 Million | CN¥41.09 Million | — |